Attached files

file filename
EX-99.1 - EARNINGS RELEASE - SPECTRANETICS CORPa2014ex991q2earningsrelease.htm
EX-99.2 - PRESS RELEASE - SPECTRANETICS CORPa2014ex992isrindication.htm


 
 
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  July 23, 2014
 
The Spectranetics Corporation
(Exact name of registrant as specified in its charter)
 
 
Delaware
 
000-19711
 
84-0997049
 
 
(State or other jurisdiction
 
(Commission
 
(IRS Employer
 
 
of incorporation)
 
File Number)
 
Identification No.)
 
 
9965 Federal Drive
Colorado Springs, Colorado 80921
(Address of principal executive offices) (Zip Code)

(719) 633-8333
Registrant's telephone number, including area code
 
(Former name or former address, if changed since last report.)
  
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 








ITEM 2.02.        Results of Operations and Financial Condition.
 
On July 24, 2014, we issued a press release that sets forth our results of operations for the three and six months ended June 30, 2014.  A copy of the press release is furnished as Exhibit 99.1.  The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of The Spectranetics Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

ITEM 8.01.        Other Events.

On July 23, 2014, we issued a press release announcing U.S. Food and Drug Administration (“FDA”) 510(k) clearance of our peripheral laser atherectomy devices for in-stent restenosis (“ISR”). A copy of the press release is filed as Exhibit 99.2.


 
ITEM 9.01         Financial Statements and Exhibits.
 
(d) Exhibits
 
99.1    Press release issued by The Spectranetics Corporation on July 24, 2014.

99.2    Press release issued by The Spectranetics Corporation on July 23, 2014.




 






2




 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
THE SPECTRANETICS
 
 
CORPORATION
 
 
 
 
 
 
Date:
July 24, 2014
By:
/s/ Jeffrey A. Sherman
 
 
 
Jeffrey A. Sherman
 
 
 
Vice President, Deputy General Counsel and Corporate Secretary
 
 
 
 
 








3




 
EXHIBIT INDEX
 

Exhibit No.


99.1    Press release issued by The Spectranetics Corporation on July 24, 2014.

99.2    Press release issued by The Spectranetics Corporation on July 23, 2014.


 







4